Treatment Trials

5 Clinical Trials for Various Conditions

Focus your search

      RECRUITING
      Long-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Adolescent ORION-16 or ORION-13 Studies
      Description

      The purpose of this open-label, single arm, multicenter extension study is to evaluate the long-term safety and tolerability of inclisiran in participants with HeFH or HoFH who have completed the ORION-16 or ORION-13 studies.

      Conditions
      Heterozygous or Homozygous Familial Hypercholesterolemia
      Talk to us
      COMPLETED
      Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C
      Description

      The purpose of this extension study was to evaluate the efficacy, safety, and tolerability of long-term dosing of Inclisiran. The study was a global multicenter study.

      Conditions
      ASCVDElevated CholesterolHeterozygous Familial HypercholesterolemiaHomozygous Familial Hypercholesterolemia
      Talk to us
      COMPLETED
      Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Children With Inherited Elevated Low-density Lipoprotein Cholesterol (Familial Hypercholesterolemia)
      Description

      The main purpose of this study is to describe the safety and tolerability of 80 weeks of subcutaneous (SC) evolocumab when added to standard of care in children 10 to 17 years of age with familial hypercholesterolemia.

      Conditions
      Familial Hypercholesterolemia
      Talk to us
      COMPLETED
      An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia
      Description

      To evaluate the safety and efficacy of extended dosing with mipomersen (ISIS 301012) in participants with familial hypercholesterolemia or severe hypercholesterolemia on lipid-lowering therapy who had completed either the 301012-CS5 (NCT00607373), 301012-CS7 (NCT00706849), 301012-CS17 (NCT00477594) or MIPO3500108 (NCT00794664) clinical drug trials.

      Conditions
      Lipid Metabolism, Inborn ErrorsHypercholesterolemia, Autosomal DominantHyperlipidemiasMetabolic DiseasesHyperlipoproteinemia Type IIMetabolism, Inborn ErrorsGenetic Diseases, InbornInfant, Newborn, DiseasesMetabolic DisorderCongenital AbnormalitiesHypercholesterolemiaHyperlipoproteinemiasDyslipidemiasLipid Metabolism Disorders
      Talk to us
      COMPLETED
      Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
      Description

      The purpose of this study is to evaluate the safety and efficacy of extended dosing of mipomersen in patients with familial hypercholesterolemia on lipid-lowering therapy who have completed either the 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008) clinical drug trials.

      Conditions
      Lipid Metabolism, Inborn ErrorsHypercholesterolemia, Autosomal DominantHyperlipidemiasMetabolic DiseasesHyperlipoproteinemia Type IIMetabolism, Inborn ErrorsGenetic Diseases, InbornInfant, Newborn, DiseasesMetabolic DisorderCongenital AbnormalitiesHypercholesterolemiaHyperlipoproteinemiasDyslipidemiasLipid Metabolism Disorders
      Talk to us